Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 02 May 2017, Paris - France

Session Details

Poster Session 1: Chronic heart failure
Sat 29 Apr 08:30 - 17:30 Miscellaneous Poster Session Poster Area -

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
08:30P272What is the incidence of elevated pulmonary artery pressure amongst patients presenting to the incident heart failure clinic?Abdallah AL-MOHAMMAD (Sheffield, United Kingdom)
08:30P273Pulmonary and cardiac characteristics of heart failure patients comparing three groups based on left-ventricular ejection fractionWouter ROBAEYS (Maastricht, Netherlands)
08:30P274Comparing mildly-reduced with preserved ejection fraction heart failure patients: two flips of the same coin?Bernardo NEVES (Lisboa, Portugal)
08:30P277Do we treat heart failure differently according to gender?Irene RILO MIRANDA (Donostia, Spain)
08:30P278Hemodynamic effects of levosimendan in advanced but stable chronic heart failureEmil NAJJAR (Sodertalje, Sweden)
08:30P281Characteristics of newly diagnosed patients with heart failure managed in the primary care and cardiology settings in FranceSara BRUCE WIRTA (Basel, Switzerland)
08:30P283Suboptimal dosing of common heart failure treatments in newly diagnosed patients with heart failure: a retrospective population-based cohort study in SwedenBernt Gerhard WIKSTROM (Uppsala, Sweden)
08:30P284Management of patients with heart failure with preserved versus reduced ejection fraction: a retrospective population-based cohort study in SwedenBernt Gerhard WIKSTROM (Uppsala, Sweden)
08:30P285Long-term effects of patiromer for hyperkalaemia treatment in patients with HFrEF and diabetic nephropathy on RAASiBertram PITT (Ann Arbor, United States of America)
08:30P286Drug treatment patterns in patients newly diagnosed with heart failure: a retrospective population-based cohort study in SwedenBernt Gerhard WIKSTROM (Uppsala, Sweden)
08:30P287Degree of dyspnoea at admission and discharge in patients with heart failure and respiratory diseases Lourdes VICENT ALAMINOS (Madrid, Spain)
08:30P288The role of IGFBP7, mimecan and osteopontin in the management of heart failure with preserved and reduced ejection fraction.Nick MARCKS (Echt, Netherlands)
08:30P289Coenzyme Q-10 in treatment of patients with heart failure: Results Russian multicenter double blind placebo controlled studyViatcheslav MAREEV (Moscow, Russian Federation)
08:30P290Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fractionEun-Seok JEON (Seoul, Korea Republic of)
08:30P291Beta blockers and chronic heart failure: prognostic impact of a dose targeted therapy vs. heart rate targeted strategyAnna CORLETTO (Muenchen, Germany)
08:30P292The impact of digoxin on mortality in patients with chronic systolic heart failureMay KHATEEB (Riyadh, Saudi Arabia)
08:30P293Comparison of outcome in systolic heart failure patients using ivabradine, digoxin or neither of them: a real life studyDilek URAL (Istanbul, Turkey)
08:30P294NTproBNP in primary care: initial experience.Juan Luis BONILLA PALOMAS (Cordoba, Spain)
08:30P295Ivabradine reduces rehospitalization in patients with chronic systolic heart failure: single country data from OPTIMIZE- HF programHamayak SISAKIAN (Yerevan, Armenia)
08:30P296An audit exploring the effectiveness in medical data recording on implementation of an inpatient heart failure proformaHugh William Lynch BETHELL (Henley, United Kingdom)
08:30P298Ceiling dose of valsartan improves better ventricular-vascular coupling index than usual dose in severe heart failureWook-Jin CHUNG (Incheon, Korea Republic of)
08:30P300Observational Study of the Therapeutic Conduct in Patients with Heart Failure in Mexico: Baseline population characteristics.Jose Antonio MAGANA SERRANO (Mexico, Mexico)
08:30P301The effect of ivabradine on reduction of heart rate and improvement of the quality of life in patients with angina or heart failure in morocco.Ahmed BENNIS (Casablanca, Morocco)
08:30P302Red cell distribution width: an easily available parameter and an independent predictor of mortality in chronic heart failureSara GONCALVES (Charneca De Caparica, Portugal)
08:30P303Prognostic significance of asymptomatic hyperuricemia and allopurinol therapy in chronic systolic HF outpatientsRossella BANI (Sesto Fiorentino, Italy)
08:30P305The role of simple clinical indicators in the assessment of prognosis in patients with stable systolic heart failureMariia SITNIKOVA (St-Petersburg, Russian Federation)
08:30P306Phase angle by bioelectrical impedance vector analysis as predictor of prolonged hospital stayLeslie VERDEJA VENDRELL (Puebla, Mexico)
08:30P307The association between left ventricular ejection fraction, previous chronic heart failure and mortality in patients with acute coronary syndrome (data of Russian RECORD-3 registry)Alexey ERLIKH (Moscow, Russian Federation)
08:30P308Prognostic markers in heart failure patients with mid-range ejection fractionIlya GIVERTS (Moscow, Russian Federation)
08:30P309Can thyroid function be a predictor of poor prognosis in heart failure?Sara GONCALVES (Charneca De Caparica, Portugal)
08:30P310Left ventricular remodeling and inflammation features as predicting factors of sudden cardiac death after myocardial infarctionElena BYKOVA (St-Petersburg, Russian Federation)
08:30P311Echocardiography parameters in heart failure patients with moderate functional mitral regurgitation and correlation with six months outcomeFarveh VAKILIAN AGHOUEE (Mashhad, Iran (Islamic Republic of))
08:30P312Improving heart failure care in hospitals with and without a multidiscipinary heart failure program:results from optimize Colombia project Clara Ines SALDARRIAGA (Medellin, Colombia)
08:30P313Prognostic impact of the combined presence of anemia and chronic kidney disease on long-term mortality in patients with reduced and preserved ejection fraction following myocardial infarctionLidija SAVIC (Beograd, Serbia)
08:30P314Gender difference of obesity paradox in systolic heart failureByungsu YOO (Wonju, Korea Republic of)
08:30P315Clinical predictors of mortality in patients with severe aortic stenosis undergoing surgical and percutaneous aortic valve interventionJoao Pedro Ribeiro AGOSTINHO (Lisboa, Portugal)
08:30P317Prognostic impact of glycated hemoglobin in patients with systolic heart failureEleonore HEBBAR (Lambersart, France)
08:30P318Prognostic importance of inclusion serum cystatin C level for eGFR calculation by CKD-EPI equation in patients with first decompensation of HFPEFDmitry SHCHEKOCHIKHIN (Moscow, Russian Federation)
08:30P319A simplified bedside prognostic tool for heart failure: the proSCANNED scoreKamila SOLECKI (Montpellier Cedex 5, France)
08:30P320Heart rate response to exercise in heart failure patients: the prognostic role of metabolic-chronotropic relation and heart rate recoveryJan BENES (Praha 4- Michle, Czech Republic)
08:30P321A re-examination of the beta-blocker evaluation of survival trial (BEST) using composite outcomes including emergency department visitsLi SHEN (Glasgow, United Kingdom)
08:30P322Hospitalization for heart failure following cardiac resynchronization therapy: Impact in mortalityMaria TREPA (Porto, Portugal)
08:30P323Long-term prognostic information of BNP levels in patients with stable systolic heart failureThomas MERCIER (Lille, France)
08:30P324Prevalence and prognostic impact of co-morbidities in heart failure: data from the Slovenian national heart failure registryMaja PUSNIK VRCKOVNIK (Slovenj Gradec, Slovenia)
08:30P325Patient phenotypes and outcome in heart failure: a national hospitalization database cluster analysisDaniel OMERSA (Kranj, Slovenia)
08:30P326Hyperphosphatemia is a predictor of poor prognosis in patients with chronic heart failureElena REZNIK (Moscow, Russian Federation)
08:30P327Prevalence and determinant of cognitive impairment in elderly patients with heart failure - A pilot study in a geriatric hospitalShutaro FUTAMI (Tokyo, Japan)
08:30P330Probability of cardiovascular events in chronic heart failure patients with preserved and mid-range ejection fraction depending on different phenotypes of peripheral arterial systemAnastasia SHCHENDRYGINA (Moscow, Russian Federation)
08:30P331Influence and management of diabetes mellitus in patients with heart failure with reduced ejection fraction followed in a non-tertiary hospital heart failure unit.Virgilio MARTINEZ MATEO (Alcazar De San Juan, Spain)
08:30P332Characteristics of patients with chronic heart failure according to new ESC guidelines derived-LVEF classificationDamien LOGEART (Courbevoie, France)
08:30P334The prevalence of rhythm and conduction disorders in three different types of heart failureEgle TAMULENAITE (Kaunas, Lithuania)
08:30P335The relationship between the buckberg index and functional capacity in stable chronic heart failure patients.Tara MANNION (Dublin, Ireland)
08:30P336Understanding heart failure with middle range ejection fraction: results from a Colombian populationClara Ines SALDARRIAGA (Medellin, Colombia)
08:30P337Non-invasive cardiac output monitoring after cardiopulmonary exercise testing in patients with heart failureEmilia SAWICKA (Bialystok, Poland)
08:30P338Change in the precipitating factors of heart failure admission in patients included in a heart failure unitZorba BLAZQUEZ BERMEJO (Madrid, Spain)
08:30P339Optimize Brazil - Analysis of a multidisciplinary approach in a multicenter brazilian cohort to optimize heart failure treatmentPedro SCHWARTZMANN (Ribeirao Preto, Brazil)
08:30P341Outcome of a transitional care clinic to reduce heart failure readmission in high-risk inner city populationJustin LEE (Brooklyn, United States of America)
08:30P345Impact of ejection fraction on the clinical features in heart failure patients with concominant chronic obstructive pulmonary diseaseVioletta GAZIZIANOVA (Kazan, Russian Federation)
08:30P346The effectiveness of tolvaptan does not correlate with the severity of hyponatremiaRarsari Soerarso PRATIKTO (Jakarta, Indonesia)